ABBOTT LABORATORIES
For the period ended Oct 21, 2026. Filed Oct 21, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 21, 2026 · Filed Oct 21, 2026
Contents
EX-99.1 · Diagnostics*
Diagnostics*
| Sales 3Q26 ($ in millions) | Total | Core Laboratory | Cancer Diagnostics | Rapid/Molecular Diagnostics |
|---|---|---|---|---|
| U.S. | 1,853 | 389 | 938 | 526 |
| International | 1,452 | 1,049 | 30 | 373 |
| Total reported | 3,305 | 1,438 | 968 | 899 |
| U.S. | 109.2 | 6.3 | n/a | 1.1 | |
|---|---|---|---|---|---|
| International | 6.2 | 5.1 | n/a | 1.0 | |
| Total reported | 46.7 | 5.4 | n/a | 1.1 | |
| Total reported excl. foreign exchange impact | 46.6 | 5.4 | n/a | 0.9 | |
| Comparable sales growth | 6.4 | 5.4 | 13.8 | 0.9 | |
| U.S. | 8.4 | 6.3 | 13.9 | 1.1 | |
| International | 4.0 | 5.1 | 12.1 | 0.7 |
Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.
Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.
Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.
| Sales 9M26 ($ in millions) | Total | Core Laboratory | Cancer Diagnostics | Rapid/Molecular Diagnostics |
|---|---|---|---|---|
| U.S. | 4,418 | 1,113 | 1,921 | 1,384 |
| International | 4,159 | 3,015 | 62 | 1,082 |
| Total reported | 8,577 | 4,128 | 1,983 | 2,466 |
| U.S. | 72.0 | 6.1 | n/a | (8.9) | |
|---|---|---|---|---|---|
| International | 6.3 | 5.8 | n/a | 1.9 | |
| Total reported | 32.4 | 5.9 | n/a | (4.5) | |
| Total reported excl. foreign exchange impact | 30.8 | 4.0 | n/a | (5.4) | |
| Comparable sales growth | 3.8 | 4.0 | 13.5 | (5.4) | |
| U.S. | 4.9 | 6.1 | 13.5 | (8.9) | |
| International | 2.4 | 3.2 | 15.0 | (0.4) |
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.